{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:11:54Z","timestamp":1777050714216,"version":"3.51.4"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,3]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Anti-<jats:italic toggle=\"yes\">N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate receptor (NMDAR) encephalitis is a rare disease of nervous system, which is mediated by autoimmune mechanisms. The treatment of anti-NMDAR encephalitis includes Immunotherapy, symptomatic and supportive treatment for seizures and psychiatric symptoms. There are many kinds of drugs, so drug treatment management and pharmaceutical care for children are particularly important. At present, there are few reports on pharmaceutical care for children with this disease. Clinical pharmacists participated in the pharmaceutical care of a child with refractory anti-NMDAR encephalitis treated with rituximab, conducted drug treatment management on the dosage, administration method, complications and other aspects of off-label use of rituximab, combined with the children\u2019s clinical manifestations, inflammatory indicators, pathogenic detection, blood concentration, liver and kidney functions, drug interactions and other factors. The treatment plan of anti-infective drugs shall be adjusted, and attention shall be paid to whether there are adverse reactions during the treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 4-year-old girl presented with epileptic seizure, intermittent recurrent fever, high inflammatory markers, abnormal psychiatric function\/cognitive impairment, language disorder, consciousness disturbance, and movement disorder\/involuntary movement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Refractory anti-NMDAR encephalitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was given first-line (3 rounds of methylprednisolone pulse therapy and gamma globulin) and second-line (rituximab) immunotherapy. On the advice of a clinical pharmacist, the patient wasn\u2019t given Advanced antibacterial agents (voriconazole, vancomycin) therapy. On the 41st day of admission, the patient\u2019s temperature and inflammatory indicators were normal, CD19<jats:sup>+<\/jats:sup> B cells were reduced to 0.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient consciousness level, cognition and orientation were gradually improved, mental disorder was improved, involuntary movement was obviously controlled, no seizure occurred again, and the patient was discharged with stable condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Clinical pharmacists ensure the safety, effectiveness and economy of patients\u2019 medication by carrying out the whole process of individualized drug treatment management and care for patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032843","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T15:12:18Z","timestamp":1675782738000},"page":"e32843","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pharmaceutical care of rituximab in the treatment of children with refractory anti-NMDAR encephalitis: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2550-0290","authenticated-orcid":false,"given":"Haiyan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Shandong First Medical University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qixuan","family":"Ding","sequence":"additional","affiliation":[{"name":"School of Clinical Pharmacy, Shandong First Medical University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of Clinical Pharmacy, Shandong First Medical University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaozhen","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Clinical Pharmacy, Shandong First Medical University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liaocheng People\u2019s Hospital, Liaocheng, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Central Hospital Affiliated to Shandong First Medical University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma.","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"577753","DOI":"10.1016\/j.jneuroim.2021.577753","article-title":"The changing spectrum of antibody-mediated encephalitis in China.","volume":"361","author":"Ren","year":"2021","journal-title":"J Neuroimmunol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/cid\/cir1038","article-title":"The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project.","volume":"54","author":"Gable","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/brain\/awq113","article-title":"N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1212\/NXI.0000000000000130","article-title":"Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome.","volume":"2","author":"Byrne","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/WNL.0b013e31822cfc6b","article-title":"Analysis of relapses in anti-NMDAR encephalitis.","volume":"77","author":"Gababilondo","year":"2011","journal-title":"Neurology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/dmcn.14267","article-title":"Relapse risk factors in anti-N-methyl-d-aspartate receptor encephalitis.","volume":"61","author":"Nosadini","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"R10-20250504","first-page":"931","article-title":"Chinese expert consensus on the diagnosis and management of autoimmune encephalitis (2022 edition).","volume":"55","year":"2022","journal-title":"Chin J Neurol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optic after repeated therapy with rituximab.","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1212\/NXI.0000000000001052","article-title":"International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis.","volume":"8","author":"Nosadini","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2019.02.008","article-title":"Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: an observation study in Chinese patients.","volume":"330","author":"Deng","year":"2019","journal-title":"J Neuroimmunol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2017.04.007","article-title":"Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour.","volume":"377","author":"Wang","year":"2017","journal-title":"Neurol Sci"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol"},{"key":"R17-20250504","first-page":"38","article-title":"Clinical characteristics of autoimmune Encephalitis in Children.","volume":"47","author":"Guan","year":"2021","journal-title":"Chin J Nerv Ment Dis"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/jnnp-2012-303807","article-title":"Paediatric autoimmune encephalopathies-clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens.","volume":"84","author":"Hacohen","year":"2013","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"R19-20250504","first-page":"45","article-title":"Influence of carbapenem antibiotics on plasma concentration of sodium valproate.","volume":"13","author":"Li","year":"2016","journal-title":"Anti Infect Pharm"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tcmj.2012.02.008","article-title":"Interaction between valproic acid and carbapenems: case series and literature review.","volume":"24","author":"Lee","year":"2012","journal-title":"Tzu Chi Med J"},{"key":"R21-20250504","first-page":"1364","article-title":"Interaction of valproic acid and carbapenem antibiotics.","volume":"3l","author":"Li","year":"2012","journal-title":"Herald Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"690.e1","DOI":"10.1016\/j.ajem.2019.09.011","article-title":"Meropenem as an antidote for intentional valproic acid overdose.","volume":"38","author":"Thomas","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1378\/chest.13-1490","article-title":"Challenges in providing critical care for patients with anti-N-methyl-d-aspartate receptor encephalitis.","volume":"145","author":"Howard","year":"2014","journal-title":"Chest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:45:02Z","timestamp":1746326702000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032843","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}